cellgenisys mit krebsvaccine zu neuen höhen - 500 Beiträge pro Seite
eröffnet am 20.02.04 15:21:36 von
neuester Beitrag 29.03.04 14:22:05 von
neuester Beitrag 29.03.04 14:22:05 von
Beiträge: 18
ID: 824.469
ID: 824.469
Aufrufe heute: 0
Gesamt: 1.599
Gesamt: 1.599
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| gestern 20:17 | 1214 | |
| 08.05.24, 11:56 | 865 | |
| gestern 22:26 | 519 | |
| gestern 17:59 | 503 | |
| 10.05.24, 22:06 | 495 | |
| vor 1 Stunde | 456 | |
| heute 04:46 | 411 | |
| heute 00:58 | 373 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 18.772,85 | +0,46 | 131 | |||
| 2. | 3. | 0,2170 | +3,33 | 125 | |||
| 3. | Neu! | 8,2570 | +96,67 | 108 | |||
| 4. | 4. | 156,46 | -2,31 | 103 | |||
| 5. | 14. | 5,7540 | -2,18 | 56 | |||
| 6. | 2. | 0,2980 | -3,87 | 50 | |||
| 7. | 5. | 2,3720 | -7,54 | 49 | |||
| 8. | 7. | 6,8000 | +2,38 | 38 |
Feedback
Experimental Vaccine May Stop Lung Cancer
Thu Feb 19, 4:55 PM ET Add Health - AP to My Yahoo!
By RENEE C. LEE, Associated Press Writer
DALLAS - An experimental vaccine wiped out lung cancer in some patients and slowed its spread in others in a small but promising study, researchers say.
Three patients injected with the vaccine, GVAX, had no recurrence of lung cancer for more than three years afterward, according to the study of 43 people with the most common form of the disease, non-small cell lung cancer.
The findings were published in Wednesday`s Journal of the National Cancer Institute (news - web sites). The research was funded in part by CellGenesis, a pharmaceutical company that hopes to produce the vaccine.
The vaccine, developed by researchers at Baylor University Medical Center in Dallas, is years away from reaching the market, if ever. The researchers hope to apply for Food and Drug Administration (news - web sites) approval in three years.
"The results are very promising for patients with non-small (cell) lung cancer, which is frequently resistant to chemotherapy," said Dr. John Nemunaitis, a Baylor oncologist who led the study.
Non-small cell lung cancer is the nation`s leading cause of cancer death, killing more than 150,000 people each year. The disease is related to smoking and is often difficult to treat. Treatment usually involves removal of the tumor, chemotherapy or both.
Vaccine studies are a burgeoning area of cancer research. Unlike traditional vaccines, which generally aim to prevent disease, some experimental cancer vaccines are designed to treat or cure existing disease.
This study is the first to show complete and long-lasting regression of lung cancer by stimulating the immune system to attack cancer cells, Nemunaitis said. A similar approach has shown promise against skin and renal cell cancer.
In the study, each patient was injected in the arm and leg with a vaccine that included cells from his or her tumors. A gene called CM-CSF was placed into the cancer cells to change the surface of the cells to help the body identify them as cancerous. The body`s immune cells soon began to recognize, attack and destroy the cancer cells in the lungs.
Forty-three lung cancer patients — 10 in the early stage and 33 in the advanced stage — were injected with the vaccine every two weeks for three months. Researchers followed them for three years.
The cancer disappeared in three of the advanced-stage patients. Two of those patients previously had chemotherapy, which failed. In the rest of the advanced-stage patients, the disease remained stable and did not spread for almost five months to more than two years.
For patients in the early stage, the vaccine did not make much difference against the cancer.
"The most exciting thing is in those who responded to the vaccine, it was complete," Nemunaitis said. "It`s given us a lot of encouragement."
For patients with advanced-stage lung cancer, chemotherapy works no more than 3 percent of the time, and survival is usually eight to nine months. Those whose cancer went into remission with the vaccine were alive at least three years later. And the vaccine has no side effects, Nemunaitis said.
Dr. Anwar Khurshid, an oncologist at the Arlington Cancer Center, said the findings will "open a lot of avenues."
"I think you`ll cure some patients but not everyone. That`s what has been proven in other cases," he said. "You need to vaccine earlier or combine with something else to cure more people."
http://news.yahoo.com/news?tmpl=story&u=/ap/20040219/ap_on_h…
Thu Feb 19, 4:55 PM ET Add Health - AP to My Yahoo!
By RENEE C. LEE, Associated Press Writer
DALLAS - An experimental vaccine wiped out lung cancer in some patients and slowed its spread in others in a small but promising study, researchers say.
Three patients injected with the vaccine, GVAX, had no recurrence of lung cancer for more than three years afterward, according to the study of 43 people with the most common form of the disease, non-small cell lung cancer.
The findings were published in Wednesday`s Journal of the National Cancer Institute (news - web sites). The research was funded in part by CellGenesis, a pharmaceutical company that hopes to produce the vaccine.
The vaccine, developed by researchers at Baylor University Medical Center in Dallas, is years away from reaching the market, if ever. The researchers hope to apply for Food and Drug Administration (news - web sites) approval in three years.
"The results are very promising for patients with non-small (cell) lung cancer, which is frequently resistant to chemotherapy," said Dr. John Nemunaitis, a Baylor oncologist who led the study.
Non-small cell lung cancer is the nation`s leading cause of cancer death, killing more than 150,000 people each year. The disease is related to smoking and is often difficult to treat. Treatment usually involves removal of the tumor, chemotherapy or both.
Vaccine studies are a burgeoning area of cancer research. Unlike traditional vaccines, which generally aim to prevent disease, some experimental cancer vaccines are designed to treat or cure existing disease.
This study is the first to show complete and long-lasting regression of lung cancer by stimulating the immune system to attack cancer cells, Nemunaitis said. A similar approach has shown promise against skin and renal cell cancer.
In the study, each patient was injected in the arm and leg with a vaccine that included cells from his or her tumors. A gene called CM-CSF was placed into the cancer cells to change the surface of the cells to help the body identify them as cancerous. The body`s immune cells soon began to recognize, attack and destroy the cancer cells in the lungs.
Forty-three lung cancer patients — 10 in the early stage and 33 in the advanced stage — were injected with the vaccine every two weeks for three months. Researchers followed them for three years.
The cancer disappeared in three of the advanced-stage patients. Two of those patients previously had chemotherapy, which failed. In the rest of the advanced-stage patients, the disease remained stable and did not spread for almost five months to more than two years.
For patients in the early stage, the vaccine did not make much difference against the cancer.
"The most exciting thing is in those who responded to the vaccine, it was complete," Nemunaitis said. "It`s given us a lot of encouragement."
For patients with advanced-stage lung cancer, chemotherapy works no more than 3 percent of the time, and survival is usually eight to nine months. Those whose cancer went into remission with the vaccine were alive at least three years later. And the vaccine has no side effects, Nemunaitis said.
Dr. Anwar Khurshid, an oncologist at the Arlington Cancer Center, said the findings will "open a lot of avenues."
"I think you`ll cure some patients but not everyone. That`s what has been proven in other cases," he said. "You need to vaccine earlier or combine with something else to cure more people."
http://news.yahoo.com/news?tmpl=story&u=/ap/20040219/ap_on_h…
die homepage des unternehmen http://www.cellgenesys.com/home.shtml
weitere werte mit einem krebsipfstoff sind dendren, abgenix und geron
alle besitzen schon eine hohe marktkapitalisierung
ein kleines unternehmen mit einem krebsimpfstoff ist avax technoloigies mit einer marktkapitalisierung von etwa 10 mio dollar
die aktie eignet sich für den risikobewussten anleger denn ein totalverlust muss einkalkuliert werden jedoch sind die chancen auch enorm
Press Release Source: AVAX Technologies, Inc.
Avax Technologies Announces Publication of Data on Its Autologous Cell Vaccine
Wednesday February 11, 6:40 am ET
- Article and Editorial published in the Journal of Clinical Oncology -
OVERLAND PARK, Kan., Feb. 11 /PRNewswire-FirstCall/ -- AVAX Technologies, Inc. (OTC Bulletin Board: AVXT - News) announces the publication of a scientific paper on studies of its Autologous Cell (AC) Vaccine platform for the treatment of cancer. The paper, by David Berd, Professor of Medicine, Kimmel Cancer Center, Thomas Jefferson University and a consultant to the Company, was published as a lead article with an accompanying editorial in the February 1, 2004 issue of the Journal of Clinical Oncology.
ADVERTISEMENT
The paper is a follow-up to previously reported clinical results on 214 patients with clinical stage III melanoma who received the AC Vaccine after standard surgery. Almost all surviving patients had completed the planned five-year follow-up. The overall five-year survival for the 214 patients was 44%. It is particularly interesting that over half of these patients were stage IIIC, which has a particularly poor cure rate after surgery alone.
Berd and his coworkers found that an immune response to unmodified autologous melanoma cells, measured by delayed-type hypersensitivity (DTH), was induced in 47% of the patients. Significantly the survival of the DTH- positive group was double that of the DTH-negative patients. These results indicate that the DTH response can be a very important intermediate end point that can be used for further development of the technology.
Richard Rainey, President of AVAX stated, "We are happy that these clinical results have been published. It is particularly gratifying that that the journal considered this paper important enough to commission an editorial. The overall survival and the relationship between survival and DTH will serve as valuable markers for us in the continuing development of this therapeutic regimen given that this study confirmed the finding that patients who had positive DTH responses had significantly longer relapse-free and overall survival rates." Mr. Rainey stated further, "We believe that the immunopharmacological analysis of the patient data in the article clearly demonstrates two very important markers. First, the timing of an induction dose and second, the schedule of the administration of the vaccine are critical parameters affecting immunologic and clinical endpoints. We are continuing with our plans to develop this important therapeutic treatment and expanding the treatment to a variety of other cancers."
AVAX Technologies, Inc. is a biotechnology company with operations in the United States and Europe. The Company is engaged in the research, clinical and commercial development of biological products and cancer therapeutics. In addition the Company offers contract-manufacturing services of biological products to other pharmaceutical and biotechnology companies.
Except for statements that are historical, the statements in this release are "forward-looking" statements that are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements involve significant risks and uncertainties, and in light of the significant uncertainties inherent in such statements, the inclusion of such information should not be regarded as a representation by AVAX that the objectives and plans of the Company will be achieved. In fact, actual results could differ materially from those contemplated by such forward-looking statements. Many important factors affect the Company`s prospects, including (1) the Company`s ability to obtain substantial additional funds, beyond the announced bridge loans, (2) the Company`s ability to enter into and to maintain contract manufacturing agreements that are adequate to sustain its operations, (3) the Company`s ability to identify a merger or acquisition partner, (4) the results of laboratory testing of our vaccine technologies and the small molecule compounds, (5) possible future FDA or AFSSAPS questions regarding the Company`s products and manufacturing processes, (6) the Company`s ability to maintain its rights under license and research funding agreements and to meeting funding requirements under its license and research funding agreements, (7) the Company`s ability to demonstrate the safety and efficacy of product candidates at each stage of development and to meet applicable regulatory standards and receive required regulatory approvals, as well as other risks detailed from time to time in AVAX`s public disclosure filings with the Securities and Exchange Commission, including its Annual Report on Form 10-KSB for the year ended December 31, 2002. AVAX does not undertake any obligation to release publicly any revisions to these forward-looking statements or to reflect the occurrence of unanticipated events.
alle besitzen schon eine hohe marktkapitalisierung
ein kleines unternehmen mit einem krebsimpfstoff ist avax technoloigies mit einer marktkapitalisierung von etwa 10 mio dollar
die aktie eignet sich für den risikobewussten anleger denn ein totalverlust muss einkalkuliert werden jedoch sind die chancen auch enorm
Press Release Source: AVAX Technologies, Inc.
Avax Technologies Announces Publication of Data on Its Autologous Cell Vaccine
Wednesday February 11, 6:40 am ET
- Article and Editorial published in the Journal of Clinical Oncology -
OVERLAND PARK, Kan., Feb. 11 /PRNewswire-FirstCall/ -- AVAX Technologies, Inc. (OTC Bulletin Board: AVXT - News) announces the publication of a scientific paper on studies of its Autologous Cell (AC) Vaccine platform for the treatment of cancer. The paper, by David Berd, Professor of Medicine, Kimmel Cancer Center, Thomas Jefferson University and a consultant to the Company, was published as a lead article with an accompanying editorial in the February 1, 2004 issue of the Journal of Clinical Oncology.
ADVERTISEMENT
The paper is a follow-up to previously reported clinical results on 214 patients with clinical stage III melanoma who received the AC Vaccine after standard surgery. Almost all surviving patients had completed the planned five-year follow-up. The overall five-year survival for the 214 patients was 44%. It is particularly interesting that over half of these patients were stage IIIC, which has a particularly poor cure rate after surgery alone.
Berd and his coworkers found that an immune response to unmodified autologous melanoma cells, measured by delayed-type hypersensitivity (DTH), was induced in 47% of the patients. Significantly the survival of the DTH- positive group was double that of the DTH-negative patients. These results indicate that the DTH response can be a very important intermediate end point that can be used for further development of the technology.
Richard Rainey, President of AVAX stated, "We are happy that these clinical results have been published. It is particularly gratifying that that the journal considered this paper important enough to commission an editorial. The overall survival and the relationship between survival and DTH will serve as valuable markers for us in the continuing development of this therapeutic regimen given that this study confirmed the finding that patients who had positive DTH responses had significantly longer relapse-free and overall survival rates." Mr. Rainey stated further, "We believe that the immunopharmacological analysis of the patient data in the article clearly demonstrates two very important markers. First, the timing of an induction dose and second, the schedule of the administration of the vaccine are critical parameters affecting immunologic and clinical endpoints. We are continuing with our plans to develop this important therapeutic treatment and expanding the treatment to a variety of other cancers."
AVAX Technologies, Inc. is a biotechnology company with operations in the United States and Europe. The Company is engaged in the research, clinical and commercial development of biological products and cancer therapeutics. In addition the Company offers contract-manufacturing services of biological products to other pharmaceutical and biotechnology companies.
Except for statements that are historical, the statements in this release are "forward-looking" statements that are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements involve significant risks and uncertainties, and in light of the significant uncertainties inherent in such statements, the inclusion of such information should not be regarded as a representation by AVAX that the objectives and plans of the Company will be achieved. In fact, actual results could differ materially from those contemplated by such forward-looking statements. Many important factors affect the Company`s prospects, including (1) the Company`s ability to obtain substantial additional funds, beyond the announced bridge loans, (2) the Company`s ability to enter into and to maintain contract manufacturing agreements that are adequate to sustain its operations, (3) the Company`s ability to identify a merger or acquisition partner, (4) the results of laboratory testing of our vaccine technologies and the small molecule compounds, (5) possible future FDA or AFSSAPS questions regarding the Company`s products and manufacturing processes, (6) the Company`s ability to maintain its rights under license and research funding agreements and to meeting funding requirements under its license and research funding agreements, (7) the Company`s ability to demonstrate the safety and efficacy of product candidates at each stage of development and to meet applicable regulatory standards and receive required regulatory approvals, as well as other risks detailed from time to time in AVAX`s public disclosure filings with the Securities and Exchange Commission, including its Annual Report on Form 10-KSB for the year ended December 31, 2002. AVAX does not undertake any obligation to release publicly any revisions to these forward-looking statements or to reflect the occurrence of unanticipated events.
wkn von avax 920934
die aktie wird auch in berlin gehandelt jesoch ist dass handelsvolumen mehr als dürftig
die homepage des unternehmen http://www.avax-tech.com/
die aktie wird auch in berlin gehandelt jesoch ist dass handelsvolumen mehr als dürftig
die homepage des unternehmen http://www.avax-tech.com/
die angabe der marktkapitalisierung im yahoo board ist leider falsch gewesen. tut mir leid
AVAX Technologies Announces Results of Special Shareholders Meeting
Tuesday February 3, 5:00 pm ET
OVERLAND PARK, Kan., Feb. 3 /PRNewswire-FirstCall/ -- AVAX Technologies, Inc. (OTC Bulletin Board: AVXT - News) today announces that a proposed amendment to its Certificate of Incorporation to increase its number of authorized shares of common stock from 50 million to 150 million was approved at its special meeting of shareholders held on January 29, 2004.
ADVERTISEMENT
Richard Rainey, President of AVAX, stated, "It was very important for the Company that the shareholders voted to increase our authorized capital. This will allow us more flexibility in structuring future financial transactions."
AVAX Technologies, Inc. is a biotechnology company with operations in the United States and Europe. The Company is engaged in the research, clinical and commercial development of biological products and cancer therapeutics. In addition the Company offers contract-manufacturing services of biological products to other pharmaceutical and biotechnology companies.
Except for statements that are historical, the statements in this release are "forward-looking" statements that are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements involve significant risks and uncertainties, and in light of the significant uncertainties inherent in such statements, the inclusion of such information should not be regarded as a representation by AVAX that the objectives and plans of the Company will be achieved. In fact, actual results could differ materially from those contemplated by such forward-looking statements. Many important factors affect the Company`s prospects, including (1) the Company`s ability to obtain substantial additional funds, beyond the announced bridge loans, (2) the Company`s ability to enter into and to maintain contract manufacturing agreements that are adequate to sustain its operations, (3) the Company`s ability to identify a merger or acquisition partner, (4) the results of laboratory testing of our vaccine technologies and the small molecule compounds, (5) possible future FDA or AFSSAPS questions regarding the Company`s products and manufacturing processes, (6) the Company`s ability to maintain its rights under license and research funding agreements and to meeting funding requirements under its license and research funding agreements, (7) the Company`s ability to demonstrate the safety and efficacy of product candidates at each stage of development and to meet applicable regulatory standards and receive required regulatory approvals, as well as other risks detailed from time to time in AVAX`s public disclosure filings with the Securities and Exchange Commission, including its Annual Report on Form 10-KSB for the year ended December 31, 2002. AVAX does not undertake any obligation to release publicly any revisions to these forward-looking statements or to reflect the occurrence of unanticipated events
AVAX Technologies Announces Results of Special Shareholders Meeting
Tuesday February 3, 5:00 pm ET
OVERLAND PARK, Kan., Feb. 3 /PRNewswire-FirstCall/ -- AVAX Technologies, Inc. (OTC Bulletin Board: AVXT - News) today announces that a proposed amendment to its Certificate of Incorporation to increase its number of authorized shares of common stock from 50 million to 150 million was approved at its special meeting of shareholders held on January 29, 2004.
ADVERTISEMENT
Richard Rainey, President of AVAX, stated, "It was very important for the Company that the shareholders voted to increase our authorized capital. This will allow us more flexibility in structuring future financial transactions."
AVAX Technologies, Inc. is a biotechnology company with operations in the United States and Europe. The Company is engaged in the research, clinical and commercial development of biological products and cancer therapeutics. In addition the Company offers contract-manufacturing services of biological products to other pharmaceutical and biotechnology companies.
Except for statements that are historical, the statements in this release are "forward-looking" statements that are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements involve significant risks and uncertainties, and in light of the significant uncertainties inherent in such statements, the inclusion of such information should not be regarded as a representation by AVAX that the objectives and plans of the Company will be achieved. In fact, actual results could differ materially from those contemplated by such forward-looking statements. Many important factors affect the Company`s prospects, including (1) the Company`s ability to obtain substantial additional funds, beyond the announced bridge loans, (2) the Company`s ability to enter into and to maintain contract manufacturing agreements that are adequate to sustain its operations, (3) the Company`s ability to identify a merger or acquisition partner, (4) the results of laboratory testing of our vaccine technologies and the small molecule compounds, (5) possible future FDA or AFSSAPS questions regarding the Company`s products and manufacturing processes, (6) the Company`s ability to maintain its rights under license and research funding agreements and to meeting funding requirements under its license and research funding agreements, (7) the Company`s ability to demonstrate the safety and efficacy of product candidates at each stage of development and to meet applicable regulatory standards and receive required regulatory approvals, as well as other risks detailed from time to time in AVAX`s public disclosure filings with the Securities and Exchange Commission, including its Annual Report on Form 10-KSB for the year ended December 31, 2002. AVAX does not undertake any obligation to release publicly any revisions to these forward-looking statements or to reflect the occurrence of unanticipated events
Trading Spotlight
Cell Genesys gehören heute zu den Kursgewinnern im Biotechnologie-Sektor, nachdem eine medizinische Fachzeitschrift über das Potential des in Entwicklung befindlichen Krebswirkstoffes des Unternehmens berichtete. Die Aktie gewinnt um 10.88% auf $14.27. Die Testergebnisse aus einer Phase III Studie für das Medikament seien zwar bereits veröffentlicht worden, so Analyst Mark Monane von Needham Co. Doch sorge die Veröffentlichung der Daten in einem angesehenen medizinischen Fachblatt für weitere Bestätigung für den Wirkstoff.
So erfolgreich können impfungen bei krebs sein
dieser bericht ist von heute
Nierenkrebs - Wirksamkeit von Impfstoff nachgewiesen
Die Impfung mit einem aus eigenen Tumorzellen hergestellten Mittel verringert das Wiedererkrankungsrisiko nach einer Nierenkrebsoperation. Das belegt eine Studie der Universität Lübeck mit 379 Patienten. Nach Angaben der hannoverschen Biotechnologie-Firma Liponova, die den Impfstoff entwickelt hat, handelt es sich um den weltweit ersten Nachweis der Wirksamkeit eines solches MIttels. Durch den Impfstoff verringere sich das Risiko einer Wiedererkrankung beziehungsweise der Bildung neuer Metastasen um etwa 30 Prozent.
Impfstoff aus Tumorzellen gewonnen
Für die Impfung hatten die Forscher in Zusammenarbeit mit Liponova Tumorzellen der Patienten aufgespalten und ihre Gefährlichkeit vermindert. Den daraus gewonnenen Impfstoff erhielten die Patienten der Testgruppe nach der Operation im Abstand von vier Wochen sechs Mal unter die Haut gespritzt. Aus den Studienergebnissen schließen die Forscher, dass die Zusatztherapie nach der Operation bei Nierentumoren mit einer Größe von mehr als 2,5 Zentimetern Durchmesser empfohlen werden kann.
Wissenschaftsmagazin stellt Forschungsergebnisse vor
Die Lübecker Wissenschaftler präsentieren die Ergebnisse ihrer Studie im britischen Fachmagazin "The Lancet". Im Rahmen der Untersuchung wurden die Patienten in eine Test- und eine Kontrollgruppe aufgeteilt. Während die Personen der Testgruppe nach der Nierenkrebsoperation mit dem Impfstoff behandelt wurden, erhielten die Teilnehmer der Kontrollgruppe nach der Operation keine zusätzliche Impfung. Fünf Jahre nach der Operation lebten 77 Prozent der Testgruppe ohne einen Rückfall. In der Kontrollgruppe waren es 68 Prozent. Nach weiteren zehn Monaten waren es 72 Prozent in der Test- und 59 Prozent in der Kontrollgruppe.
"Durchbruch für die Immunologie"
In Deutschland erkranken jährlich rund 14.000 Menschen an Nierenkrebs. Zwei Kommentatoren des "Lancet" bezeichneten den Forschungserfolg als "Durchbruch für die Immunologie". Derzeit gebe es keine allgemein akzeptierte begleitende Therapie nach einer Nierenkrebs-Operation. Nach Angaben der Hannoverschen Allgemeinen Zeitung ist die 18.000 Euro teure Impfung bereits möglich, wird bislang aber nicht von den Krankenkassen bezahlt.
Biotech-Unternehmen auf Expansionskurs
Liponova hat bereits im vergangenen Dezember die europaweite Zulassung für das Verfahren beantragt und rechnet mit einer Zulassung Anfang 2005. Liponova beschäftigt derzeit 25 Mitarbeiter. Bis zum Jahresende sollen 15 weitere hinzukommen, berichtet eine Firmensprecherin.
dieser bericht ist von heute
Nierenkrebs - Wirksamkeit von Impfstoff nachgewiesen
Die Impfung mit einem aus eigenen Tumorzellen hergestellten Mittel verringert das Wiedererkrankungsrisiko nach einer Nierenkrebsoperation. Das belegt eine Studie der Universität Lübeck mit 379 Patienten. Nach Angaben der hannoverschen Biotechnologie-Firma Liponova, die den Impfstoff entwickelt hat, handelt es sich um den weltweit ersten Nachweis der Wirksamkeit eines solches MIttels. Durch den Impfstoff verringere sich das Risiko einer Wiedererkrankung beziehungsweise der Bildung neuer Metastasen um etwa 30 Prozent.
Impfstoff aus Tumorzellen gewonnen
Für die Impfung hatten die Forscher in Zusammenarbeit mit Liponova Tumorzellen der Patienten aufgespalten und ihre Gefährlichkeit vermindert. Den daraus gewonnenen Impfstoff erhielten die Patienten der Testgruppe nach der Operation im Abstand von vier Wochen sechs Mal unter die Haut gespritzt. Aus den Studienergebnissen schließen die Forscher, dass die Zusatztherapie nach der Operation bei Nierentumoren mit einer Größe von mehr als 2,5 Zentimetern Durchmesser empfohlen werden kann.
Wissenschaftsmagazin stellt Forschungsergebnisse vor
Die Lübecker Wissenschaftler präsentieren die Ergebnisse ihrer Studie im britischen Fachmagazin "The Lancet". Im Rahmen der Untersuchung wurden die Patienten in eine Test- und eine Kontrollgruppe aufgeteilt. Während die Personen der Testgruppe nach der Nierenkrebsoperation mit dem Impfstoff behandelt wurden, erhielten die Teilnehmer der Kontrollgruppe nach der Operation keine zusätzliche Impfung. Fünf Jahre nach der Operation lebten 77 Prozent der Testgruppe ohne einen Rückfall. In der Kontrollgruppe waren es 68 Prozent. Nach weiteren zehn Monaten waren es 72 Prozent in der Test- und 59 Prozent in der Kontrollgruppe.
"Durchbruch für die Immunologie"
In Deutschland erkranken jährlich rund 14.000 Menschen an Nierenkrebs. Zwei Kommentatoren des "Lancet" bezeichneten den Forschungserfolg als "Durchbruch für die Immunologie". Derzeit gebe es keine allgemein akzeptierte begleitende Therapie nach einer Nierenkrebs-Operation. Nach Angaben der Hannoverschen Allgemeinen Zeitung ist die 18.000 Euro teure Impfung bereits möglich, wird bislang aber nicht von den Krankenkassen bezahlt.
Biotech-Unternehmen auf Expansionskurs
Liponova hat bereits im vergangenen Dezember die europaweite Zulassung für das Verfahren beantragt und rechnet mit einer Zulassung Anfang 2005. Liponova beschäftigt derzeit 25 Mitarbeiter. Bis zum Jahresende sollen 15 weitere hinzukommen, berichtet eine Firmensprecherin.
Cell Genesys to Webcast Presentation at the BIO CEO & Investor Conference
Monday February 23, 7:30 am ET
SOUTH SAN FRANCISCO, Calif., Feb. 23 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. (Nasdaq: CEGE - News), today announced that Stephen A. Sherwin, M.D., chairman and chief executive officer of Cell Genesys, will present a company update at the BIO CEO & Investor Conference in New York, NY that will be broadcast live over the internet on Wednesday, February 25, 2004 at 12:00 p.m. EST.
The webcast will be available on the Investor Relations section of the Cell Genesys website, www.cellgenesys.com. If you are unable to listen to the live webcast, it will be archived on the site for at least 48 hours following the presentation. To access the replay, go to the Investor Relations section of the website.
Cell Genesys is focused on the development and commercialization of novel biological therapies for patients with cancer. The company is pursuing three cancer product platforms -- GVAX® cancer vaccines, oncolytic virus therapies and antiangiogenesis therapies. Clinical trials of GVAX® vaccines are under way in prostate cancer, lung cancer, pancreatic cancer, leukemia and myeloma. Clinical programs of oncolytic virus therapies include CG7870 for prostate cancer. Preclinical studies are in progress for additional GVAX® cancer vaccines, oncolytic virus therapies and antiangiogenesis therapies for multiple types of cancer. Cell Genesys` majority-owned subsidiary, Ceregene, Inc., is focused on gene therapies for neurologic disorders. Cell Genesys also continues to hold an equity interest in its former subsidiary, Abgenix, Inc., an antibody products company. Cell Genesys is headquartered in South San Francisco, CA and has manufacturing operations in San Diego, CA, Hayward, CA and Memphis, TN. For additional information, please visit the company`s website at www.cellgenesys.com.
Monday February 23, 7:30 am ET
SOUTH SAN FRANCISCO, Calif., Feb. 23 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. (Nasdaq: CEGE - News), today announced that Stephen A. Sherwin, M.D., chairman and chief executive officer of Cell Genesys, will present a company update at the BIO CEO & Investor Conference in New York, NY that will be broadcast live over the internet on Wednesday, February 25, 2004 at 12:00 p.m. EST.
The webcast will be available on the Investor Relations section of the Cell Genesys website, www.cellgenesys.com. If you are unable to listen to the live webcast, it will be archived on the site for at least 48 hours following the presentation. To access the replay, go to the Investor Relations section of the website.
Cell Genesys is focused on the development and commercialization of novel biological therapies for patients with cancer. The company is pursuing three cancer product platforms -- GVAX® cancer vaccines, oncolytic virus therapies and antiangiogenesis therapies. Clinical trials of GVAX® vaccines are under way in prostate cancer, lung cancer, pancreatic cancer, leukemia and myeloma. Clinical programs of oncolytic virus therapies include CG7870 for prostate cancer. Preclinical studies are in progress for additional GVAX® cancer vaccines, oncolytic virus therapies and antiangiogenesis therapies for multiple types of cancer. Cell Genesys` majority-owned subsidiary, Ceregene, Inc., is focused on gene therapies for neurologic disorders. Cell Genesys also continues to hold an equity interest in its former subsidiary, Abgenix, Inc., an antibody products company. Cell Genesys is headquartered in South San Francisco, CA and has manufacturing operations in San Diego, CA, Hayward, CA and Memphis, TN. For additional information, please visit the company`s website at www.cellgenesys.com.
meislo,
bist Du schon investiert?
Die Aktie könnte mich auch interessieren.
Falls Du weitere Info`s postest in der nächsten Zeit, bin ich ein interessierter Leser.
KMS
bist Du schon investiert?
Die Aktie könnte mich auch interessieren.
Falls Du weitere Info`s postest in der nächsten Zeit, bin ich ein interessierter Leser.
KMS
Warum schmieren die heute so ab?
Wer weiß was?
KMS
Wer weiß was?
KMS
Investor Profile: Lappin sails against the tide
Tuesday February 24, 4:01 pm ET
By Elizabeth Lazarowitz
NEW YORK, Feb 24 (Reuters) - When Joan Lappin got into money management, female fund managers were few and far between. She has been going against the grain ever since, flagging the questionable accounting at Qwest Communications Inc. (NYSE:Q - News) years before it turned from Wall Street darling to dog.
ADVERTISEMENT
The secret, she said, is learning to tune out the voices of Wall Street`s conventional wisdom and relying instead on her own research and instincts.
"My first claim to fame was investing very successfully about 20 years ago in Immunex, when everybody thought I was a nutcase" for buying it, Lappin said. "You don`t make money owning things that everybody knows about already."
Lappin, 61, is chairman and chief executive of New York-based investment adviser Gramercy Capital Management Corp., a company she founded in 1986.
Lappin looks for companies with interesting products and a solid business plan that are neither spending too much money nor hoarding too much cash.
Gramercy Capital`s largest holding is credit card issuer Providian Financial Corp. (NYSE:PVN - News), a stock Lappin bought in the range of $4 to $6 per share nearly two years ago. It now trades around $13. Barclays Plc recently ended talks to buy the company, sources said, but Lappin still believes the stage is set for the stock to reach $20.
In 2003 -- a year when the Standard & Poor`s 500 index (CBOE:^SPX - News) rose 26 percent -- she helped her wealthy clients rack up a return of 31 percent in her more conservative portfolios and 36 percent in her more aggressive ones.
Biotechnology is an area where Lappin expects to find some winners, as the big drug companies, largely bereft of new products, turn to deals with biotech companies. About 15 percent to 18 percent of her assets are invested in the sector, with Cephalon Inc.(NasdaqNM:CEPH - News) and Cell Genesys Inc. (NasdaqNM:CEGE - News), among her picks.
With the economy sputtering along toward recovery, Lappin says the key to success in the market is savvy stock picking.
"This is not going to be an easy year," she said. "A rising tide will not lift all boats the way it did in 2003."
While Lappin`s professional prowess has made her recommendations a hot commodity, getting her voice heard was not so easy more than 30 years ago, when women in power positions on Wall Street were rare.
Lappin -- just 20 when she earned a bachelor`s degree in history from the University of Wisconsin, Madison, in 1964 -- worked as a teacher and then a bank teller. Her introduction to investments came while she was a secretary at Manufacturer`s Hanover in the department that managed the bank`s own money.
When her father slammed the door on her full-time business school aspirations, saying she was "just doing it to evade work," she took classes at night and eventually got a Masters of Business Administration degree from New York University.
One company Lappin worked for in the late 1960s planned a meeting at the New York Exchange`s Luncheon Club which, at the time, banned women. The meeting was moved to another room at the exchange, but even so she was taken there in the service elevator "with the janitor, mop and bucket," she said.
Lappin spent 15 years working as a media analyst, and then in 1980, she began managing investment portfolios at Manufacturers Hanover Trust.
She later managed money for Arnhold & S. Bleichroeder, but left not long after receiving an annual bonus of $5,000 -- an amount she considered meager given the 38 percent return she had brought in for the company on the assets she was managing.
It may have been a blessing in disguise. She then set out on her own with Gramercy Capital, a company she named for the tony Manhattan neighborhood where she lived at the time.
Lappin, who has two adult children, is an avid sailor, and spends summer weekends on a 36-foot sloop she keeps in Rhode Island.
Lappin is known for being both blunt and outspoken.
In the spring of 2003, when many investors were still shellshocked from three years of stock market declines, Lappin predicted the bear market was at an end.
In an article in Physicians Money Digest on May 31, 2003, she pointed to the large percentage of people who were bullish on bonds and the small percentage bullish on stocks (84 percent and 21 percent, respectively in March, according to Market Vane) as indication it was time to buy stocks.
"Following the crowd never tends to be a winning strategy for more than a very short time," Lappin wrote.
Now that investors have largely shed their fear of getting back into stocks and the market has rallied sharply in the past year, the obvious bets have already been made, Lappin said.
"The market just needs a little bit of rest here," Lappin said. "Now, you have the challenge that you have to buy companies that have something special going on that are really going to help them keep moving forward."
ne och bin nicht investiert da ich bri geron ziemlich dick investiert bin
cellgenisys und geron haben ein gemeinschaftsprojekt ´dass von seiten geron immer gelobt wird. leider hört man dazu aber nichts von cellgenisys
bei diesem projekt ist demnächst wohl mit klinischen testphasen zurechnen.
es handelt sich um genmanipulierte adenovieren deren erbgut so verändert wurden dass sie sich auf telomerase stürzen und die zellen in denen telomerase überkomprimiert vorkommt, zerstören. dazu muss man wissen dass telomerase in den meisten krebszellen in hoher dosis vorhanden ist. auf diese art und weise wird der tumor durch die viren angegriffen und zerstört. allerdings kommt telomerase auch in bestimmten körperzellen vor. z.b hautzellen, keimbahnen und andere. bisher sind aber bei vielen tests keine nebenwirkungen bei telomeraseblockaden festgestell worden. geron besitzt eine patentvielfallt auf diesem gebiet. geron hat aber diese technologie an unterschiedliche firmen auslizensiert oder aber kooperationen geschlossen.so auch im fall cellgenesys
hier ein auszug aus einer präsentation von dem chef der firma geron
Let`s turn quickly to the oncolytic virus. This is a genetically engineered virus in which we control the replication of the virus with the telomerase promoter, the on/off switch. So the only way the virus can replicate and kill the cell it`s replicating in is if it`s in a telomerase positive tumor cell. And we and GTI/Novartis have published on the specificity of this virus before. So what I want to show you here is work also done at GTI that shows synergy of this virus with doxyrubicin. So here we`re measuring tumor volume, the spread or growth of the tumor, of a liver cancer in an animal. The virus alone is shown here in blue with a effect that is significant over control. Here is doxyrubicin by itself. At this dose slightly more potent than the virus by itself. But in these two lines we see the combination of that dose of virus and that dose of doxyrubicin, which is literally complete control of the tumor. Very dramatic synergy. And, again, because we control the replication of the virus elegantly to telomerase, there`s no adverse events in these animals. So we look forward to the continued development of this technology with Cell Genesys
Tuesday February 24, 4:01 pm ET
By Elizabeth Lazarowitz
NEW YORK, Feb 24 (Reuters) - When Joan Lappin got into money management, female fund managers were few and far between. She has been going against the grain ever since, flagging the questionable accounting at Qwest Communications Inc. (NYSE:Q - News) years before it turned from Wall Street darling to dog.
ADVERTISEMENT
The secret, she said, is learning to tune out the voices of Wall Street`s conventional wisdom and relying instead on her own research and instincts.
"My first claim to fame was investing very successfully about 20 years ago in Immunex, when everybody thought I was a nutcase" for buying it, Lappin said. "You don`t make money owning things that everybody knows about already."
Lappin, 61, is chairman and chief executive of New York-based investment adviser Gramercy Capital Management Corp., a company she founded in 1986.
Lappin looks for companies with interesting products and a solid business plan that are neither spending too much money nor hoarding too much cash.
Gramercy Capital`s largest holding is credit card issuer Providian Financial Corp. (NYSE:PVN - News), a stock Lappin bought in the range of $4 to $6 per share nearly two years ago. It now trades around $13. Barclays Plc recently ended talks to buy the company, sources said, but Lappin still believes the stage is set for the stock to reach $20.
In 2003 -- a year when the Standard & Poor`s 500 index (CBOE:^SPX - News) rose 26 percent -- she helped her wealthy clients rack up a return of 31 percent in her more conservative portfolios and 36 percent in her more aggressive ones.
Biotechnology is an area where Lappin expects to find some winners, as the big drug companies, largely bereft of new products, turn to deals with biotech companies. About 15 percent to 18 percent of her assets are invested in the sector, with Cephalon Inc.(NasdaqNM:CEPH - News) and Cell Genesys Inc. (NasdaqNM:CEGE - News), among her picks.
With the economy sputtering along toward recovery, Lappin says the key to success in the market is savvy stock picking.
"This is not going to be an easy year," she said. "A rising tide will not lift all boats the way it did in 2003."
While Lappin`s professional prowess has made her recommendations a hot commodity, getting her voice heard was not so easy more than 30 years ago, when women in power positions on Wall Street were rare.
Lappin -- just 20 when she earned a bachelor`s degree in history from the University of Wisconsin, Madison, in 1964 -- worked as a teacher and then a bank teller. Her introduction to investments came while she was a secretary at Manufacturer`s Hanover in the department that managed the bank`s own money.
When her father slammed the door on her full-time business school aspirations, saying she was "just doing it to evade work," she took classes at night and eventually got a Masters of Business Administration degree from New York University.
One company Lappin worked for in the late 1960s planned a meeting at the New York Exchange`s Luncheon Club which, at the time, banned women. The meeting was moved to another room at the exchange, but even so she was taken there in the service elevator "with the janitor, mop and bucket," she said.
Lappin spent 15 years working as a media analyst, and then in 1980, she began managing investment portfolios at Manufacturers Hanover Trust.
She later managed money for Arnhold & S. Bleichroeder, but left not long after receiving an annual bonus of $5,000 -- an amount she considered meager given the 38 percent return she had brought in for the company on the assets she was managing.
It may have been a blessing in disguise. She then set out on her own with Gramercy Capital, a company she named for the tony Manhattan neighborhood where she lived at the time.
Lappin, who has two adult children, is an avid sailor, and spends summer weekends on a 36-foot sloop she keeps in Rhode Island.
Lappin is known for being both blunt and outspoken.
In the spring of 2003, when many investors were still shellshocked from three years of stock market declines, Lappin predicted the bear market was at an end.
In an article in Physicians Money Digest on May 31, 2003, she pointed to the large percentage of people who were bullish on bonds and the small percentage bullish on stocks (84 percent and 21 percent, respectively in March, according to Market Vane) as indication it was time to buy stocks.
"Following the crowd never tends to be a winning strategy for more than a very short time," Lappin wrote.
Now that investors have largely shed their fear of getting back into stocks and the market has rallied sharply in the past year, the obvious bets have already been made, Lappin said.
"The market just needs a little bit of rest here," Lappin said. "Now, you have the challenge that you have to buy companies that have something special going on that are really going to help them keep moving forward."
ne och bin nicht investiert da ich bri geron ziemlich dick investiert bin
cellgenisys und geron haben ein gemeinschaftsprojekt ´dass von seiten geron immer gelobt wird. leider hört man dazu aber nichts von cellgenisys
bei diesem projekt ist demnächst wohl mit klinischen testphasen zurechnen.
es handelt sich um genmanipulierte adenovieren deren erbgut so verändert wurden dass sie sich auf telomerase stürzen und die zellen in denen telomerase überkomprimiert vorkommt, zerstören. dazu muss man wissen dass telomerase in den meisten krebszellen in hoher dosis vorhanden ist. auf diese art und weise wird der tumor durch die viren angegriffen und zerstört. allerdings kommt telomerase auch in bestimmten körperzellen vor. z.b hautzellen, keimbahnen und andere. bisher sind aber bei vielen tests keine nebenwirkungen bei telomeraseblockaden festgestell worden. geron besitzt eine patentvielfallt auf diesem gebiet. geron hat aber diese technologie an unterschiedliche firmen auslizensiert oder aber kooperationen geschlossen.so auch im fall cellgenesys
hier ein auszug aus einer präsentation von dem chef der firma geron
Let`s turn quickly to the oncolytic virus. This is a genetically engineered virus in which we control the replication of the virus with the telomerase promoter, the on/off switch. So the only way the virus can replicate and kill the cell it`s replicating in is if it`s in a telomerase positive tumor cell. And we and GTI/Novartis have published on the specificity of this virus before. So what I want to show you here is work also done at GTI that shows synergy of this virus with doxyrubicin. So here we`re measuring tumor volume, the spread or growth of the tumor, of a liver cancer in an animal. The virus alone is shown here in blue with a effect that is significant over control. Here is doxyrubicin by itself. At this dose slightly more potent than the virus by itself. But in these two lines we see the combination of that dose of virus and that dose of doxyrubicin, which is literally complete control of the tumor. Very dramatic synergy. And, again, because we control the replication of the virus elegantly to telomerase, there`s no adverse events in these animals. So we look forward to the continued development of this technology with Cell Genesys
AF hat wohl cellgenisys unter beschuss genommen vielleicht ist dass der grund für den einbruch. dazu muss man wissen dass AF gerne gegen biotechs wettert. er verdient wohl gut an den shortpositionen. mit geron treibter ein ähnliches spiel.
I`m hearing from good sources that Cell Genesys (CEGE:Nasdaq) was forced to halt a phase II lung cancer study of its GVAX personalized cancer vaccine after three patients died during surgery to collect tumor tissue used to make the vaccine. These same sources tell me that Cell Genesys is trying to amend the study protocol in order to get the study restarted, but it`s not yet clear whether the FDA or data-safety monitors will allow it.
I want to emphasize that I`m still trying to nail down all the facts here, and I`ve been unable so far to reach anyone at Cell Genesys for comment. But as you can see, the stock is sinking this morning, so I felt it important to let you know what I`m hearing -- and my sources are pretty good on this one. Cell Genesys will be making a presentation at the BIO CEO conference in about an hour, so I would assume more details are coming.
http://find.thestreet.com/cgi-bin/texis/rmfind/results.html?…
gruss meislo
I`m hearing from good sources that Cell Genesys (CEGE:Nasdaq) was forced to halt a phase II lung cancer study of its GVAX personalized cancer vaccine after three patients died during surgery to collect tumor tissue used to make the vaccine. These same sources tell me that Cell Genesys is trying to amend the study protocol in order to get the study restarted, but it`s not yet clear whether the FDA or data-safety monitors will allow it.
I want to emphasize that I`m still trying to nail down all the facts here, and I`ve been unable so far to reach anyone at Cell Genesys for comment. But as you can see, the stock is sinking this morning, so I felt it important to let you know what I`m hearing -- and my sources are pretty good on this one. Cell Genesys will be making a presentation at the BIO CEO conference in about an hour, so I would assume more details are coming.
http://find.thestreet.com/cgi-bin/texis/rmfind/results.html?…
gruss meislo
Hallo KMS
hier ein link zur präsentation auf der biokonferenz von heute
du musst dich nur registrieren lassen und das kostet nichts
hab ich auch gemacht
dann kannst du dir die präsentation anhören
http://www.firstcallevents.com/service/ajwz401067584gf12.htm…
hier ein link zur präsentation auf der biokonferenz von heute
du musst dich nur registrieren lassen und das kostet nichts
hab ich auch gemacht
dann kannst du dir die präsentation anhören
http://www.firstcallevents.com/service/ajwz401067584gf12.htm…
Cell Genesys Refuses Rumor Comments
by: not_the_same_guy 03/05/04 08:52 am
Msg: 14238 of 14240
From TheRoad.com
Cell Genesys Refuses to Release Inside Information
Friday March 5, 8:38 am ET
By Deep Throat, TheRoad.com Senior Writer
After playing playing by the rules for more than a week, Cell Genesys (NasdaqNM:CEGE - News) filed its 10k discussing its financials, upcoming trials and the modifications to ongoing trials. Street.com writer Adam Feuerstein had made attempts to get the company to comment on inside information he had obtained, but the company refused in line with SEC guidelines.
Mr. Feuerstein first attempts at manipulation included claims that one of the many cancer trials had been halted. This story was then altered to claim that the company would have difficulty completing the trial. The report in Cell Genesys`s 10k notes that small number of high risk patients would no longer be allowed in the trials.
Currently, the mean survival rate for such patients is under 5 months and without treatment, a small number of these (5% to 10%) would be expected to die within the first month. Previously, it had been noted that the GVAX vaccine extended life to close to 11 months in these patients.
In their filing, Cell Genesys also noted that 2 out of 3 patients with one type of non small-cell lung cancer, bronchoalveolar carcinoma, showed complete response to the vaccine.
With 40,000 diagnosed with lung cancer each year in the UK and over 180,000 in the United States, there is not likely to be a shortage of potential patients. Furthermore, the recent publication in the February 18, 2004 issue of the Journal of the National Cancer Institute received worldwide press with stories in over 400 publications worldwide . Here at Road.com, we have heard rumors that that this press has resulted in "many thousands" of new requests to enroll in the trials.
We applaud Cell Genesys for not responding to the shameless journalistic tactics of the Street.com and hope they continue their professional approach to handling such rumors and distortions.
by: not_the_same_guy 03/05/04 08:52 am
Msg: 14238 of 14240
From TheRoad.com
Cell Genesys Refuses to Release Inside Information
Friday March 5, 8:38 am ET
By Deep Throat, TheRoad.com Senior Writer
After playing playing by the rules for more than a week, Cell Genesys (NasdaqNM:CEGE - News) filed its 10k discussing its financials, upcoming trials and the modifications to ongoing trials. Street.com writer Adam Feuerstein had made attempts to get the company to comment on inside information he had obtained, but the company refused in line with SEC guidelines.
Mr. Feuerstein first attempts at manipulation included claims that one of the many cancer trials had been halted. This story was then altered to claim that the company would have difficulty completing the trial. The report in Cell Genesys`s 10k notes that small number of high risk patients would no longer be allowed in the trials.
Currently, the mean survival rate for such patients is under 5 months and without treatment, a small number of these (5% to 10%) would be expected to die within the first month. Previously, it had been noted that the GVAX vaccine extended life to close to 11 months in these patients.
In their filing, Cell Genesys also noted that 2 out of 3 patients with one type of non small-cell lung cancer, bronchoalveolar carcinoma, showed complete response to the vaccine.
With 40,000 diagnosed with lung cancer each year in the UK and over 180,000 in the United States, there is not likely to be a shortage of potential patients. Furthermore, the recent publication in the February 18, 2004 issue of the Journal of the National Cancer Institute received worldwide press with stories in over 400 publications worldwide . Here at Road.com, we have heard rumors that that this press has resulted in "many thousands" of new requests to enroll in the trials.
We applaud Cell Genesys for not responding to the shameless journalistic tactics of the Street.com and hope they continue their professional approach to handling such rumors and distortions.
Cell Genesys to issue 6 million shares
Thursday March 4, 5:47 pm ET
SEATTLE, March 4 (Reuters) - Cell Genesys Inc. (NasdaqNM:CEGE - News), a cancer vaccine drug company, said on Thursday it filed to offer 6 million shares of its stock to the public.
The offering, made under an existing shelf registration, also gives underwriters the option of purchasing an additional 900,000 shares if the cash call has over-allotments.
JP Morgan and Lehman Brothers are acting as joint book-running managers, while Needham & Company and SG Cowen are co-managers.
Shares of Cell Genesys rallied 12 percent last month after an article in a medical journal reviewed data that showed one of the company`s experimental cancer vaccines demonstrated dramatic success in a small number of patients.
Thursday March 4, 5:47 pm ET
SEATTLE, March 4 (Reuters) - Cell Genesys Inc. (NasdaqNM:CEGE - News), a cancer vaccine drug company, said on Thursday it filed to offer 6 million shares of its stock to the public.
The offering, made under an existing shelf registration, also gives underwriters the option of purchasing an additional 900,000 shares if the cash call has over-allotments.
JP Morgan and Lehman Brothers are acting as joint book-running managers, while Needham & Company and SG Cowen are co-managers.
Shares of Cell Genesys rallied 12 percent last month after an article in a medical journal reviewed data that showed one of the company`s experimental cancer vaccines demonstrated dramatic success in a small number of patients.
Cell Genesys to Present Preclinical Data From GVAX(R) Cancer Vaccine and Other Programs at 2004 AACR Annual Meeting
Thursday March 25, 7:01 am ET
SOUTH SAN FRANCISCO, Calif., March 25 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. (Nasdaq: CEGE - News) today announced that each of its five submitted abstracts have been accepted for presentation at the 2004 American Association for Cancer Research (AACR) Annual Meeting which will take place in Orlando, FL, March 27 through March 31. The five abstracts to be presented by Cell Genesys scientists are as follows:
-- Enhancement of GM-CSF secreting tumor cell vaccines by docetaxel
through immune-dependent and independent mechanisms. (To be presented
in a poster discussion by Rodney Prell, Ph.D. -- Monday, March 29,
8:00am - 12:00pm EST) (Abstract ID: 2195)
-- Oncolytic adenovirus CG5757 for the treatment of retinoblastoma (Rb)
pathway-defective and telomerase-positive cancers. (To be presented in
mini-symposia by Yuanhao Li, Ph.D. -- Monday, March 29, 9:40am EST)
(Abstract ID: 2337)
-- Adeno-associated virus (AAV) vector mediated gene transfer of soluble
VEGF receptors for the treatment of glioblastoma multiforme. (To be
presented in a poster discussion by Thomas Harding, Ph.D. -- Monday,
March 29, 1:00pm - 5:00pm EST) (Abstract ID: 2560)
-- Adeno-associated viral (AAV)-mediated gene delivery of soluble vascular
endothelial growth factor receptor 3 (sVEGFR3) inhibits development of
lymph node metastases. (To be presented in mini-symposia by JianMin
Lin, Ph.D. -- Monday, March 29, 2:40 pm EST) (Abstract ID: 2377)
-- Development of an orthotopic bladder tumor model in mice and
demonstration of antitumor efficacy with an oncolytic adenovirus CG8840
for the treatment of bladder cancer. (To be presented in a poster
discussion by Nagarajan Ramesh, Ph.D. -- Wednesday, March 31,
8:00am - 12:00pm EST) (Abstract ID: 5134)
"We are pleased to have the opportunity to present progress reports from our preclinical programs in cancer biological therapies," stated Peter K. Working, Ph.D., senior vice president, research and development at Cell Genesys. "While our business focus remains on our clinical-stage programs in GVAX® cancer vaccines and oncolytic virus therapies, our deep product pipeline represents opportunities for the future growth of our business."
Cell Genesys is focused on the development and commercialization of biological therapies for patients with cancer. The company is pursuing three cancer product platforms -- GVAX® cancer vaccines, oncolytic virus therapies and antiangiogenesis therapies. Clinical trials of GVAX® vaccines are under way in prostate cancer, lung cancer, pancreatic cancer, leukemia and myeloma. Clinical programs of oncolytic virus therapies include CG7870 for prostate cancer. Preclinical studies are in progress for additional GVAX® cancer vaccines, oncolytic virus therapies and antiangiogenesis therapies for multiple types of cancer. Cell Genesys` majority-owned subsidiary, Ceregene, Inc., is focused on gene therapies for neurologic disorders. Cell Genesys also continues to hold an equity interest in its former subsidiary, Abgenix, Inc., an antibody products company. Cell Genesys is headquartered in South San Francisco, CA and has manufacturing operations in San Diego, CA, Hayward, CA and Memphis, TN. For additional information, please visit the company`s website at
Thursday March 25, 7:01 am ET
SOUTH SAN FRANCISCO, Calif., March 25 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. (Nasdaq: CEGE - News) today announced that each of its five submitted abstracts have been accepted for presentation at the 2004 American Association for Cancer Research (AACR) Annual Meeting which will take place in Orlando, FL, March 27 through March 31. The five abstracts to be presented by Cell Genesys scientists are as follows:
-- Enhancement of GM-CSF secreting tumor cell vaccines by docetaxel
through immune-dependent and independent mechanisms. (To be presented
in a poster discussion by Rodney Prell, Ph.D. -- Monday, March 29,
8:00am - 12:00pm EST) (Abstract ID: 2195)
-- Oncolytic adenovirus CG5757 for the treatment of retinoblastoma (Rb)
pathway-defective and telomerase-positive cancers. (To be presented in
mini-symposia by Yuanhao Li, Ph.D. -- Monday, March 29, 9:40am EST)
(Abstract ID: 2337)
-- Adeno-associated virus (AAV) vector mediated gene transfer of soluble
VEGF receptors for the treatment of glioblastoma multiforme. (To be
presented in a poster discussion by Thomas Harding, Ph.D. -- Monday,
March 29, 1:00pm - 5:00pm EST) (Abstract ID: 2560)
-- Adeno-associated viral (AAV)-mediated gene delivery of soluble vascular
endothelial growth factor receptor 3 (sVEGFR3) inhibits development of
lymph node metastases. (To be presented in mini-symposia by JianMin
Lin, Ph.D. -- Monday, March 29, 2:40 pm EST) (Abstract ID: 2377)
-- Development of an orthotopic bladder tumor model in mice and
demonstration of antitumor efficacy with an oncolytic adenovirus CG8840
for the treatment of bladder cancer. (To be presented in a poster
discussion by Nagarajan Ramesh, Ph.D. -- Wednesday, March 31,
8:00am - 12:00pm EST) (Abstract ID: 5134)
"We are pleased to have the opportunity to present progress reports from our preclinical programs in cancer biological therapies," stated Peter K. Working, Ph.D., senior vice president, research and development at Cell Genesys. "While our business focus remains on our clinical-stage programs in GVAX® cancer vaccines and oncolytic virus therapies, our deep product pipeline represents opportunities for the future growth of our business."
Cell Genesys is focused on the development and commercialization of biological therapies for patients with cancer. The company is pursuing three cancer product platforms -- GVAX® cancer vaccines, oncolytic virus therapies and antiangiogenesis therapies. Clinical trials of GVAX® vaccines are under way in prostate cancer, lung cancer, pancreatic cancer, leukemia and myeloma. Clinical programs of oncolytic virus therapies include CG7870 for prostate cancer. Preclinical studies are in progress for additional GVAX® cancer vaccines, oncolytic virus therapies and antiangiogenesis therapies for multiple types of cancer. Cell Genesys` majority-owned subsidiary, Ceregene, Inc., is focused on gene therapies for neurologic disorders. Cell Genesys also continues to hold an equity interest in its former subsidiary, Abgenix, Inc., an antibody products company. Cell Genesys is headquartered in South San Francisco, CA and has manufacturing operations in San Diego, CA, Hayward, CA and Memphis, TN. For additional information, please visit the company`s website at
Cell Genesys Reports Synergistic Antitumor Activity for GVAX(R) Cancer Vaccine Plus Docetaxel Chemotherapy in Preclinical Studies
Monday March 29, 7:01 am ET
SOUTH SAN FRANCISCO, Calif., March 29 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. (Nasdaq: CEGE - News) today reported that GVAX® cancer vaccine and docetaxel chemotherapy exhibited synergistic antitumor activity when tested in a mouse tumor model. In these studies, mice treated with GVAX® cancer vaccine and intravenous docetaxel chemotherapy demonstrated a statistically significant, 68 percent improvement in duration of survival (52 days; p=0.014) compared to mice that received subtherapeutic doses of the vaccine alone (31 days). The median survival for mice treated with docetaxel alone or mice treated with a saline control was in both cases 24 days. These preclinical studies provide support for the company`s Phase 3 development program for its lead product, GVAX® prostate cancer vaccine, which includes two Phase 3 clinical trials, one of which will evaluate GVAX® prostate cancer vaccine in combination with docetaxel chemotherapy. These preclinical data were presented today by Cell Genesys scientists at the American Association of Cancer Research (AACR) Meeting in Orlando, FL.
ADVERTISEMENT
"We are encouraged by the preclinical studies reported today demonstrating the potential benefits of combining GVAX® cancer vaccines and docetaxel chemotherapy -- a chemotherapy which is widely used today in the treatment of several major cancers including prostate, breast and lung," stated Peter K. Working, Ph.D., senior vice president, research and development at Cell Genesys. "We believe that this combination of immunotherapy and chemotherapy may represent a new approach to the treatment of multiple types of cancer."
The preclinical studies were conducted in a melanoma mouse model, which is a commonly used to evaluate experimental cancer treatments. Mice were treated with granulocyte-macrophage colony stimulating factor (GM-CSF)-secreting tumor cells, an experimental version of GVAX® cancer vaccine, and docetaxel following challenge with B16 melanoma cells. Statistically significant survival was observed following both single and multiple cycles of combination therapy (three doses each of vaccine and docetaxel) compared to treatment with docetaxel or vaccine alone. These studies also showed that docetaxel enhanced the expansion and survival of tumor-specific immune T cells, a possible mechanism for its enhancement of the vaccine potency. No dose-limiting toxicities were observed following combination therapy with docetaxel and GVAX® cancer vaccine.
Cell Genesys is planning to conduct two Phase 3 clinical trials of GVAX® prostate cancer vaccine in hormone-refractory patients with radiologic evidence of metastatic disease -- one in asymptomatic patients without cancer-related pain, which will compare GVAX® vaccine to docetaxel chemotherapy with respect to survival benefit, and one in symptomatic patients, which will compare GVAX® vaccine plus docetaxel chemotherapy to chemotherapy alone with respect to reduction in bone pain. Cell Genesys recently conducted a clinical End of Phase 2 meeting with the Food and Drug Administration (FDA), and based on the outcome of this meeting, expects to initiate the first Phase 3 trial in asymptomatic patients by the end of the second quarter of 2004. The company plans to manufacture GVAX® prostate cancer vaccine for Phase 3 trials and potential market launch in its bioreactor manufacturing facility in Hayward, California.
Clinical trials of GVAX® cancer vaccines are underway for multiple types of cancer, including prostate cancer, lung cancer, pancreatic cancer, leukemia and myeloma. Cell Genesys` GVAX® cancer vaccines are whole-cell vaccines that are designed to stimulate an immune response against the patient`s tumor. The vaccines are comprised of tumor cells that have been genetically modified to secrete GM-CSF, an immune stimulatory hormone that plays a key role in stimulating the body`s immune response to vaccines.
Cell Genesys is focused on the research, development and commercialization of biological therapies for patients with cancer. The company is pursuing three cancer product platforms -- GVAX® cancer vaccines, oncolytic virus therapies and antiangiogenesis therapies. Clinical trials of GVAX® vaccines are under way in prostate cancer, lung cancer, pancreatic cancer, leukemia and myeloma. Clinical programs of oncolytic virus therapies include CG7870 for prostate cancer. Preclinical studies are in progress for additional GVAX® cancer vaccines, oncolytic virus therapies and antiangiogenesis therapies for multiple types of cancer. Cell Genesys` majority-owned subsidiary, Ceregene, Inc., is focused on gene therapies for neurologic disorders. Cell Genesys also continues to hold an equity interest in its former subsidiary, Abgenix, Inc., an antibody products company. Cell Genesys is headquartered in South San Francisco, CA and has manufacturing operations in San Diego, CA, Hayward, CA and Memphis, TN. For additional information, please visit the company`s website at
Monday March 29, 7:01 am ET
SOUTH SAN FRANCISCO, Calif., March 29 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. (Nasdaq: CEGE - News) today reported that GVAX® cancer vaccine and docetaxel chemotherapy exhibited synergistic antitumor activity when tested in a mouse tumor model. In these studies, mice treated with GVAX® cancer vaccine and intravenous docetaxel chemotherapy demonstrated a statistically significant, 68 percent improvement in duration of survival (52 days; p=0.014) compared to mice that received subtherapeutic doses of the vaccine alone (31 days). The median survival for mice treated with docetaxel alone or mice treated with a saline control was in both cases 24 days. These preclinical studies provide support for the company`s Phase 3 development program for its lead product, GVAX® prostate cancer vaccine, which includes two Phase 3 clinical trials, one of which will evaluate GVAX® prostate cancer vaccine in combination with docetaxel chemotherapy. These preclinical data were presented today by Cell Genesys scientists at the American Association of Cancer Research (AACR) Meeting in Orlando, FL.
ADVERTISEMENT
"We are encouraged by the preclinical studies reported today demonstrating the potential benefits of combining GVAX® cancer vaccines and docetaxel chemotherapy -- a chemotherapy which is widely used today in the treatment of several major cancers including prostate, breast and lung," stated Peter K. Working, Ph.D., senior vice president, research and development at Cell Genesys. "We believe that this combination of immunotherapy and chemotherapy may represent a new approach to the treatment of multiple types of cancer."
The preclinical studies were conducted in a melanoma mouse model, which is a commonly used to evaluate experimental cancer treatments. Mice were treated with granulocyte-macrophage colony stimulating factor (GM-CSF)-secreting tumor cells, an experimental version of GVAX® cancer vaccine, and docetaxel following challenge with B16 melanoma cells. Statistically significant survival was observed following both single and multiple cycles of combination therapy (three doses each of vaccine and docetaxel) compared to treatment with docetaxel or vaccine alone. These studies also showed that docetaxel enhanced the expansion and survival of tumor-specific immune T cells, a possible mechanism for its enhancement of the vaccine potency. No dose-limiting toxicities were observed following combination therapy with docetaxel and GVAX® cancer vaccine.
Cell Genesys is planning to conduct two Phase 3 clinical trials of GVAX® prostate cancer vaccine in hormone-refractory patients with radiologic evidence of metastatic disease -- one in asymptomatic patients without cancer-related pain, which will compare GVAX® vaccine to docetaxel chemotherapy with respect to survival benefit, and one in symptomatic patients, which will compare GVAX® vaccine plus docetaxel chemotherapy to chemotherapy alone with respect to reduction in bone pain. Cell Genesys recently conducted a clinical End of Phase 2 meeting with the Food and Drug Administration (FDA), and based on the outcome of this meeting, expects to initiate the first Phase 3 trial in asymptomatic patients by the end of the second quarter of 2004. The company plans to manufacture GVAX® prostate cancer vaccine for Phase 3 trials and potential market launch in its bioreactor manufacturing facility in Hayward, California.
Clinical trials of GVAX® cancer vaccines are underway for multiple types of cancer, including prostate cancer, lung cancer, pancreatic cancer, leukemia and myeloma. Cell Genesys` GVAX® cancer vaccines are whole-cell vaccines that are designed to stimulate an immune response against the patient`s tumor. The vaccines are comprised of tumor cells that have been genetically modified to secrete GM-CSF, an immune stimulatory hormone that plays a key role in stimulating the body`s immune response to vaccines.
Cell Genesys is focused on the research, development and commercialization of biological therapies for patients with cancer. The company is pursuing three cancer product platforms -- GVAX® cancer vaccines, oncolytic virus therapies and antiangiogenesis therapies. Clinical trials of GVAX® vaccines are under way in prostate cancer, lung cancer, pancreatic cancer, leukemia and myeloma. Clinical programs of oncolytic virus therapies include CG7870 for prostate cancer. Preclinical studies are in progress for additional GVAX® cancer vaccines, oncolytic virus therapies and antiangiogenesis therapies for multiple types of cancer. Cell Genesys` majority-owned subsidiary, Ceregene, Inc., is focused on gene therapies for neurologic disorders. Cell Genesys also continues to hold an equity interest in its former subsidiary, Abgenix, Inc., an antibody products company. Cell Genesys is headquartered in South San Francisco, CA and has manufacturing operations in San Diego, CA, Hayward, CA and Memphis, TN. For additional information, please visit the company`s website at
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 94 | ||
| 54 | ||
| 46 | ||
| 37 | ||
| 33 | ||
| 20 | ||
| 15 | ||
| 12 | ||
| 11 | ||
| 8 |
